All In Biotech

Drug Trial Radar · NCT00449150

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment

Last checked: Nov 19, 2026Latest source record: Aug 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 667 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

667

Actual

Start

Mar 2007

Primary completion

Jun 2009

Study completion Dec 2009

Sponsor

Lead sponsor
AEterna ZentarisIndustry
Sponsor type
Industry
First posted
Mar 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and among those aged 50 to 80, about 40% report moderate or severe urinary symptoms of prostatism. The aim of treatment is to improve patients' quality of life which primarily depends on the severity of the symptoms of BPH. Current treatments of BPH have a benefit / risk ratio which leaves room for improvement. For this study, study medication (Cetrorelix pamoate or placebo) is administered by injection in the buttocks (Intramuscular). All patients completing the double-blind portion (Week 0 to 52) are eligible to receive the active drug during the open-label part of the study (Week 52 to 90).

Conditions

  • Benign Prostatic Hypertrophy

Interventions

  • Cetrorelix 78 mg + 78 mgDrug

  • Cetrorelix 78 mg + 52 mgDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. International Prostate Symptoms Score (IPSS)Time frame: Baseline and 52 weeks

Locations

68 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical Affiliated Research Center, Inc.

    Huntsville, Alabama

  • Urology Group of Westrn Arkansas

    Fort Smith, Arkansas

  • South Orange County Medical Research Center

    Laguna Hills, California

  • California Professionnal Research

    Newport Beach, California

  • William G. Moseley

    San Diego, California

  • West Coast Clinical Research

    Tarzana, California

  • Western Clinical Research, Inc.

    Torrance, California

  • Urology Research Options

    Aurora, Colorado

  • Urologic Oncology

    Aurora, Colorado

  • Genitourinary Surgical Consultants

    Denver, Colorado

  • Connecticut Clincal Research Center

    Middlebury, Connecticut

  • South Florida Medical Research

    Aventura, Florida

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Atlantic Urological Associates

    Daytona Beach, Florida

  • Miami VACM

    Miami, Florida

  • Florida Healthcare Research

    Ocala, Florida

  • Florida Urologist Specialists

    Sarasota, Florida

  • Southeastern Research Group

    Tallahassee, Florida

  • Southwestern Medical Research Institute

    Columbus, Georgia

  • Northwestern University Feinberg School of Medecine

    Chicago, Illinois

  • Welborn Clinic

    Evansville, Indiana

  • Northeast Indiana Research, LLC

    Fort Wayne, Indiana

  • Kansas City Urology Care

    Overland Park, Kansas

  • Four Rivers Clinical Research

    Paducah, Kentucky

  • Myron I. Murdock M.D. LLC

    Greenbelt, Maryland

  • Michigan Institute of Urology

    Saint Clair Shores, Michigan

  • Washington University

    St Louis, Missouri

  • Metropolitan Urological Specialists

    St Louis, Missouri

  • Quality Clinical Research

    Omaha, Nebraska

  • Delaware Valley Urology, LLC

    Woodlane, New Jersey

  • Urology Group Of New Mexico

    Albuquerque, New Mexico

  • Medical & Clinical Research Associates

    Bay Shore, New York

  • Urological Surgeons of Long Island, Clinical Research Division

    Garden City, New York

  • New York University School of Medecine

    New York, New York

  • University Urology

    New York, New York

  • Hudson Valley Urology

    Poughkeepsie, New York

  • Northeast Urology Research

    Concord, North Carolina

  • Parkhurst Research Oganization Inc.

    Bethany, Oklahoma

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Vanderbilt University medical Center

    Nashville, Tennessee

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.